Neurocrine Biosciences Introduces INGREZZA® SPRINKLE Capsules for Dysphagia Patients

Neurocrine Biosciences, Inc. has introduced a new sprinkle formulation of its leading vesicular monoamine transporter 2 (VMAT2) inhibitor, INGREZZA® (valbenazine) capsules. This new format, called INGREZZA® SPRINKLE, is designed to assist adults with tardive dyskinesia and Huntington's disease-associated chorea who have difficulties swallowing pills. The sprinkle formulation is now available through the same network of pharmacies that distribute the original INGREZZA capsules.

Dr. Eiry W. Roberts, Chief Medical Officer at Neurocrine Biosciences, emphasized that the new formulation aims to ease the administration process for patients struggling with swallowing. The sprinkle formulation allows for one capsule, once daily dosing, similar to the original INGREZZA capsules, without requiring complex dosage adjustments. The granules from the SPRINKLE capsules can be mixed with soft foods like applesauce, yogurt, or pudding, making it easier for patients to ingest.

Katie Jackson, President of Help 4 HD International, highlighted the importance of this new option for individuals with Huntington's disease. Many of these patients experience swallowing difficulties, and the sprinkle formulation reduces the burden of pill-taking.

A survey of 250 patients with moderate-to-severe tardive dyskinesia revealed that 37% had movements that affected their ability to eat and drink, highlighting the need for easier medication administration. The U.S. Food and Drug Administration approved INGREZZA SPRINKLE on April 30, 2024, based on data showing its bioequivalence and tolerability compared to the original capsules.

The cost of INGREZZA SPRINKLE is the same as the original INGREZZA capsules. Neurocrine Biosciences offers the INBRACE® Support Program, which assists with product support and prescription fulfillment. Patients with commercial insurance might be eligible for copay assistance, and those without prescription coverage may qualify for patient assistance programs. Most patients pay $10 or less out-of-pocket for INGREZZA.

Tardive dyskinesia (TD) is a movement disorder characterized by uncontrollable, abnormal, and repetitive movements, often caused by medications that affect dopamine receptors in the brain. This condition affects around 600,000 people in the U.S. Symptoms can be severe and often irreversible.

Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder that causes motor, cognitive, and psychiatric symptoms. Chorea, an involuntary movement disorder, affects most people with HD, disrupting motor coordination, gait, swallowing, and speech. HD impacts about 41,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease.

INGREZZA is a selective VMAT2 inhibitor that targets dopamine release in the brain, aiming to reduce uncontrollable movements. It can be taken once daily with mental health regimens like antipsychotics or antidepressants. The sprinkle formulation, INGREZZA® SPRINKLE, provides an alternative for those who struggle with swallowing pills. Both formulations are available in dosages of 40 mg, 60 mg, and 80 mg.

Neurocrine Biosciences is committed to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. With a diverse portfolio of FDA-approved treatments and a robust pipeline of compounds in clinical development, the company continues to pursue innovative solutions for complex conditions.